OncoMatch/Clinical Trials/NCT07286188
Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy
Is NCT07286188 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Misoprostol Tabets for fibroids, uterine.
Treatment: Misoprostol Tabets — The goal of this double blinded randomized control trial is to evaluate the impact of misoprostol on fluid deficit during hysteroscopic myomectomies. The main questions it aims to answer are: Is there is difference in fluid deficit in patients who receive misoprostol vs placebo pre operatively for hysteroscopic myomectomies? Participants will be randomized to received 800 mcg of either rectal misoprostol prior to their hysteroscopic myomectomy or 4 tablets of placebo (ZEEBO) prior to their hysteroscopic myomectomy.
Check if I qualifyEligibility summary
For patients with Uterine Leiomyoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Northwestern · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify